Key facts
- AKDN.’s last known valuation is $23.4M (Aug 2016).
- It has raised $3.1M; the latest was Later Stage VC in Jun 2025.
- Notable investors include DNV Capital.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for AKDN.
- ·The full record, as it builds
Funding rounds
No funding rounds for AKDN. are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AKDN.
Provider of oncology biopharmaceutical research focused on developing early-stage tumor detection technologies and targeted cancer therapeutics. The company develops molecular diagnostics, cancer screening technologies, biomarker platforms and targeted therapeutics that serve healthcare providers and research institutions and enable earlier tumor identification and cancer treatment development.
- Sector
- Healthcare
- HQ
- Shenzhen, China
- Founded
- 2016
- Employees
- 1
- Ownership
- Privately Held (backing)
AKDN. doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AKDN. shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AKDN. in its N-PORT filings yet. We sweep new filings monthly.